Clinical Trial Update: Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AP-325, a GABAA receptor modulator, on insulin secretion in adults with Type 2 Diabetes has completed; results have been reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AP-325

Snippet

Sponsor: The Deutsche Diabetes Forschungsgesellschaft e.V. | Conditions: Type2 Diabetes | Phase 2 | Status: COMPLETED